A practical reference on Angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-04 and is reviewed periodically as new material appears.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Naturally occurring nickel (28Ni) consists of five stable isotopes; 58Ni, 60Ni, 61Ni, 62Ni and 64Ni; 58Ni is the most abundant at over 68%. 26 radioisotopes have been characterized; the most stable are 59Ni with a half-life of 81,000 years, 63Ni with a half-life of 101 years, and 56Ni at 6.075 days. All the other radioactive isotopes have half-lives of less than 60 hours and most of these have half-lives of less than 30 seconds. This element also has 11 known meta states.
Insulin is used to treat a number of diseases including diabetes and its acute complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Use during pregnancy is relatively safe for the baby. Insulin was formerly used in a psychiatric treatment called insulin shock therapy.
=== Georgia === Georgia first said that its military operation responded to Ossetian artillery attack on Georgian villages, and it intended to "restore constitutional order" in South Ossetia. Later, Georgia also said it aimed to resist a Russian invasion. President of Georgia Mikheil Saakashvili told journalists that around 23:00 on 7 August, Russian tanks had begun entering Georgia, causing the Georgians to respond with artillery weapons. Georgia made intercepted telephone calls public. The calls allegedly proved that entry of Georgian troops into Tskhinvali was preceded by movement of a Russian armoured regiment into South Ossetia nearly a day earlier.
platelet-derived growth factor transforming growth factor beta fibroblast growth factor insulin-like growth factor 1 insulin-like growth factor 2 vascular endothelial growth factor A vascular endothelial growth factor C epidermal growth factor interleukin 8 keratinocyte growth factor connective tissue growth factor hepatocyte growth factor stromal cell-derived factor 1 endostatin
For human and animal health, both the FDA and the EC have regulated the content levels of toxins in food and animal feed. Fusaric acid Fusarochromanone Kojic acid Lolitrem B Moniliformin 3-Nitropropionic acid Nivalenol Ochratoxins – In Australia, The Limit of Reporting (LOR) level for ochratoxin A (OTA) analyses in 20th Australian Total Diet Survey was 1 μg/kg, whereas the EC restricts the content of OTA to 5 μg/kg in cereal commodities, 3 μg/kg in processed products and 10 μg/kg in dried vine fruits. Oosporeine Patulin – Currently, this toxin has been advisably regulated on fruit products. The EC and the FDA have limited it to under 50 μg/kg for fruit juice and fruit nectar, while limits of 25 μg/kg for solid-contained fruit products and 10 μg/kg for baby foods were specified by the EC. Phomopsins Sporidesmin A Sterigmatocystin Tremorgenic mycotoxins – Five of them have been reported to be associated with molds found in fermented meats. These are fumitremorgen B, paxilline, penitrem A, verrucosidin, and verruculogen. Trichothecenes – sourced from Cephalosporium, Fusarium, Myrothecium, Stachybotrys, and Trichoderma. The toxins are usually found in molded maize, wheat, corn, peanuts and rice, or animal feed of hay and straw. Four trichothecenes, T-2 toxin, HT-2 toxin, diacetoxyscirpenol (DAS), and deoxynivalenol (DON) have been most commonly encountered by humans and animals. The consequences of oral intake of, or dermal exposure to, the toxins will result in alimentary toxic aleukia, neutropenia, aplastic anemia, thrombocytopenia and/or skin irritation.
Sources: en.wikipedia.org
=== Processed tofu === Many forms of processed tofu exist. Some processing techniques probably originate before the days of refrigeration from the need to preserve tofu or to increase its shelf life. Other production techniques are employed to create tofus with different textures and flavors.
==== 1956–60 ==== In 1956, Sports Illustrated wrote that Mizell's return would help with St. Louis's pitching, a "major problem" for the Cardinals in 1955. His first outing back on April 17 was triumphant, as he allowed 12 hits but just two runs and came within one out of a complete game in a 4–2 victory over the Cincinnati Redlegs. From May 21 through June 9, he won five straight games, though he followed that up with three straight losses from June 15 through June 26. During the winning streak, in the second game of a May 27 doubleheader, he struck out 10 hitters in a 12–2 victory over the Chicago Cubs. In the first game of a doubleheader against Pittsburgh on August 23, he threw a four-hit shutout in a 3–0 victory. On September 7, 1956, facing the Redlegs, who were second to the Braves in a close pennant race, Mizell threw a two-hit shutout in a 1–0 victory. Six days later, he threw his second consecutive shutout, beating the Giants 5–0 and allowing just four hits. He had a 3.62 ERA for the Cardinals in 1956, and his 14–14 mark was reflective of St. Louis's .500 record. Mizell's 14 wins tied with Ron Kline and Hersh Freeman for 10th in the NL, but his 14 losses tied with Sam Jones, Al Worthington, and teammate Tom Poholsky for sixth. He ranked fifth in the NL with 153 strikeouts, and his mark of 6.6 strikeouts per nine innings pitched was good for third behind Jones's 8.4 and Harvey Haddix's 6.6. However, his 92 walks were third in the NL, behind Jones's 115 and Bob Buhl's 105.
=== Gender === Over the last 33 years, a significant decrease in women's happiness leads researchers to believe that men are happier than women. In contrast, a Pew Research Centre survey found that more women are satisfied with their lives than men, overall. Other research has found no gender gap in happiness. Part of these findings could be due to the way men and women differ in calculating their happiness. Women calculate the positive self-esteem, closeness in their relationships and religion. Men calculate positive self-esteem, active leisure and mental control. Therefore, neither men nor women are at greater risk of being less happy than the other. Earlier in life, women are more likely than men to fulfill their goals (material goals and family life aspirations), thereby increasing their life satisfaction and overall happiness. However, it is later in life that men fulfill their goals, are more satisfied with their family life and financial situation and, as a result, their overall happiness surpasses that of women. Possible explanations include the unequal division of labor within the household, or that women experience more variance (more extremes) in emotion but are generally happier. Effects of gender on well-being are paradoxical: men report feeling less happy than women, however, women are more susceptible to depression.
== Investigation == Cell-matrix adhesions have been more extensively investigated by proteomics compared with cell-cell adhesions because they are more readily isolated from cells attached to glass. The advent of proximity biotinylation by birA* has facilitated the first proteomics-based studies of the cadherin adhesome.
== Mid-20th-century innovations == After 1950, and before the advent of molecular techniques, lichenologists adopted several new approaches to refine classification. The mid-20th century brought innovations in chemical analysis and microscopy that revealed cryptic diversity and new structural characters.
Sources: en.wikipedia.org
Cell shrinkage and rounding occur because of the two parallel processes: (a) retraction of lamellipodia and the breakdown of the proteinaceous cytoskeleton by caspases and (b) water removal decreasing cytoplasmic diffusion. The cytoplasm appears dense, and the organelles appear tightly packed. Chromatin undergoes condensation into compact patches against the nuclear envelope (also known as the perinuclear envelope) in a process known as pyknosis, a hallmark of apoptosis. The nuclear envelope becomes discontinuous and the DNA inside it is fragmented in a process referred to as karyorrhexis. The nucleus breaks into several discrete chromatin bodies or nucleosomal units due to the degradation of DNA. Apoptosis progresses quickly and its products are quickly removed, making it difficult to detect or visualize on classical histology sections. During karyorrhexis, endonuclease activation leaves short DNA fragments, regularly spaced in size. These give a characteristic "laddered" appearance on agar gel after electrophoresis. Tests for DNA laddering differentiate apoptosis from ischemic or toxic cell death.
To avoid this, all radiocarbon measurements are converted to the measurement that would have been seen had the sample been made of wood, which has a known δ13C value of −25‰. Once the corrected 14C/12C ratio is known, a "radiocarbon age" is calculated using:
=== Unapproved analogues overview === Many experimental insulin analogues are being developed to improve diabetes treatment. These include new injectable types and oral forms. Oral insulin is being studied as a way to avoid injections and better match natural insulin delivery.
=== Possibility of mirror-image life === The possibility of mirror-image life has been discussed since Louis Pasteur's 1860 work on molecular asymmetry. Advances in organic chemistry and synthetic biology may, in the future, lead to the possibility of fully synthesizing a living cell from small molecules, which could enable synthesizing mirror-image cells from mirrored versions (enantiomers) of life's building-block molecules. Some important proteins in the central dogma of molecular biology have been synthesized in mirror-image versions, including DNA polymerase in 2016 and RNA polymerase in 2022. Reconstructing regular lifeforms in mirror-image form, using the mirror-image (chiral) reflection of their cellular components, could be achieved by substituting left-handed amino acids with right-handed ones, in order to create mirror reflections of proteins, and likewise substituting right-handed with left-handed nucleic acids. Because the phospholipids of cell membranes are also chiral, American geneticist George Church proposed using an achiral fatty acid instead of mirror-image phospholipids for the membrane. Electromagnetism, the dominant interaction in chemistry, is unchanged under mirror-image transformation (P-symmetry). There is a small alteration of weak interactions under reflection, which can produce very small corrections that theoretically favor the natural enantiomers of amino acids and sugars, but it is unknown if this effect is large enough to affect the functionality of mirror-image biomolecules or explain homochirality in nature.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.